Therapy News and Research

RSS

New target for Hodgkin lymphoma

Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells.

1 Aug 2007

New point of attack for future liver cancer treatments

The linking of two signalling pathways in the cells of liver tumours has a clear influence on their malignancy.

1 Aug 2007

New treatment to combat bowel infection among the elderly

Scientists at the Alimentary Pharmabiotic Centre (APC), based in University College Cork (UCC) and Teagasc’s Moorepark Food Research Centre, are researching a new treatment to combat the increasing incidences of hospital acquired diarrhoea which has become a major problem in hospitals, nursing homes and facilities for the elderly.

1 Aug 2007

Interferon alpha and sorafenib combined work better than either alone against kidney cancer

A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.

1 Aug 2007

Stem cell therapy rescues motor neurons in amyotrophic lateral sclerosis model

In a study that demonstrates the promise of cell-based therapies for diseases that have proved intractable to modern medicine, a team of scientists from the University of Wisconsin-Madison has shown it is possible to rescue the dying neurons characteristic of amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disorder also known as Lou Gehrig's disease.

31 Jul 2007

Directed nanoparticles deliver gene therapy

After binding DNA segments to tiny iron-containing spheres called nanoparticles, researchers have used magnetic fields to direct the nanoparticles into arterial muscle cells, where the DNA could have a therapeutic effect.

31 Jul 2007

Scientists show how HIV turns into AIDS

A new UC Irvine study sheds light on how HIV develops into AIDS and suggests a possible way to block the deadly transformation.

31 Jul 2007

Displaced adolescent girls benefit from group therapy

Group interpersonal psychotherapy is effective in reducing depressive symptoms among adolescent girls affected by war and displacement, according to researchers at the Johns Hopkins Bloomberg School of Public Health and other institutions. However, the same treatment was not as effective in boys.

31 Jul 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Good signal for liver tumour therapy

The linking of two signalling pathways in the cells of liver tumours has a clear influence on their malignancy. Activation of the platelet-derived growth factor (PDGF) messenger molecule is decisive for this linking.

30 Jul 2007

TB globe-trotter flies home alone!

Globe trotting tuberculosis victim, American lawyer Andrew Speaker, has been released from hospital and has returned home.

30 Jul 2007

Sexual problems of long-term cancer survivors merit more attention

The first study to look at sexual function in very long-term female survivors of genital-tract cancer found that these women were pleased with the quality of their cancer care but less satisfied with the emotional support and information they received about dealing with the effects of the disease and treatment on sexuality.

27 Jul 2007

Europe approves MIRCERA to treat anaemia

Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).

27 Jul 2007

FDA statement on gene therapy trial

On July 24, 2007 the U.S. Food and Drug Administration (FDA) was informed by Targeted Genetics Corporation of Seattle about the death of a patient who received an investigational gene therapy product in a clinical trial for the treatment of active inflammatory arthritis.

27 Jul 2007

Thiazolinediones increase risk of heart failure

A class of drugs commonly used to treat type 2 diabetes may double the risk of heart failure, according to a new analysis by researchers at Wake Forest University School of Medicine and colleagues.

27 Jul 2007

Circumcision may not actually effect sensation

According to a new study published in The Journal of Sexual Medicine, sexual sensation in circumcised and uncircumcised men may not be so different after all.

27 Jul 2007

Scientits devise dimmer swith to regulate gene expression in mammal cells

Three Boston University biomedical engineers have created a genetic dimmer switch that can be used to turn on, shut off, or partially activate a gene's function. Professor James Collins, Professor Charles Cantor and doctoral candidate Tara Deans invented the switch, which can be tuned to produce large or small quantities of protein, or none at all.

27 Jul 2007

Long-term herpes treatment may reduce HIV infectivity

Long-term anti-herpes treatment of women infected with both HIV and HSV2, the virus that causes genital herpes, may reduce the proportion of women with detectable HIV virus in their genital secretions according to the results of a trial in Tanzania presented the International AIDS Society Conference in Sydney.

26 Jul 2007

New understanding of Sly Syndrome

The scientist who discovered “Sly Syndrome” nearly four decades ago and a team of colleagues at Saint Louis University are a step closer to finding an approach to treat the rare genetic disease.

26 Jul 2007

Combination of blood pressure-lowering drugs stops loss of kidney function in rare genetic disease

A combination of two types of blood pressure-lowering drugs, an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, MA) is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.

26 Jul 2007